Isolation and Biosynthesis of an Azoxyalkene Compound Produced by a Multiple Gene Disruptant of Streptomyces rochei by Kunitake, Hirofumi et al.
広島大学学術情報リポジトリ
Hiroshima University Institutional Repository
Title Isolation and Biosynthesis of an Azoxyalkene CompoundProduced by a Multiple Gene Disruptant of Streptomyces
rochei
Auther(s) Kunitake, Hirofumi; Hiramatsu, Takahiro; Kinashi, Haruyasu;Arakawa, Kenji
Citation CHEMBIOCHEM , 16 (15) : 2237 - 2243
Issue Date 2015-10-12
DOI 10.1002/cbic.201500393
Self DOI
URL http://ir.lib.hiroshima-u.ac.jp/00048657
Right This is the peer reviewed version of the following article:CHEMBIOCHEM. 2015 Oct 12;16(15):2237-2243, which has
been published in final form at https://doi.org/10.1002/
cbic.201500393. This article may be used for non-commercial
purposes in accordance with Wiley Terms and Conditions for
Use of Self-Archived Versions.
Relation
1 
 
 
 
 
Isolation and Biosynthesis of an Azoxyalkene Compound Produced by a 
Multiple Gene Disruptant of Streptomyces rochei 
 
 
Hirofumi Kunitake, Takahiro Hiramatsu, Haruyasu Kinashi, and Kenji Arakawa*[a] 
 
 
[a] H. Kunitake, T. Hiramatsu, Prof. Dr. H. Kinashi, Prof. Dr. K. Arakawa  
Department of Molecular Biotechnology 
Graduate School of Advanced Sciences of Matter 
Hiroshima University 
1-3-1 Kagamiyama, Higashi-Hiroshima, Hiroshima 739-8530 (Japan) 
E-mail: karakawa@hiroshima-u.ac.jp. 
 
 
 
Supporting information for this article is available on the WWW under 
http://dx.doi.org/10.1002/… 
 
 
  
2 
 
Abstract 
Streptomyces rochei 7434AN4 predominantly produces lankacidin and 
lankamycin under normal culture conditions, suggesting that other biosynthetic 
gene clusters for secondary metabolites are silent. To exploit silent metabolites 
of strain 7434AN4, we constructed mutant KA57, a multiple disruptant of the 
transcriptional repressor gene srrB together with the biosynthesis genes for both 
antibiotics. Mutant KA57 accumulated a compound (KA57-A) with a strong UV 
absorption at 235 nm, which was not detected in the parent strain or other 
mutants. Various spectroscopic analyses revealed that KA57-A is an 
azoxyalkene compound of a molecular formula of C10H20N2O3 with the R 
configuration at C-2. Biosynthesis of KA57-A was also studied by feeding with 
labeled acetates, amino acids, and 1-hexylamine. The hexenyl moiety (C1’-C6’) 
was derived from fatty acid, while the 3-amino-butan-1,2-diol moiety (C1-C4) 
was derived from C-2 of acetate (C1) and serine (C2-C4). Incorporation of 
[1,1-2H2]1-hexylamine indicated that C1’-C2’ dehydrogenation occurs at the final 
step of biosynthesis. 
 
Introduction 
  The filamentous and saprophytic soil bacteria, Streptomyces, produce the 
majority (nearly 70%) of commercially available antibiotics.[1,2] To date, genome 
sequencing projects of many Streptomyces species have been completed. 
Streptomyces carry a 6- to 10-Mb linear chromosome and have a genetic 
potential to produce over 20 secondary metabolites, including polyketides, 
non-ribosomal peptides, terpenoids, aminoglycosides, and other classes of 
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metabolites.[3] However, most of the biosynthetic gene clusters for secondary 
metabolites are expressed poorly, or not expressed at all, under laboratory 
growth conditions. Several strategies to activate silent biosynthetic gene clusters 
have been reported for natural product discovery.[4,5]  
   Streptomyces rochei 7434AN4 produces two structurally unrelated 
polyketide antibiotics, lankacidin C (1) and lankamycin (2) (Scheme 1), and 
carries three linear plasmids pSLA2-L, -M, and -S.[6] The two antibiotics attracted 
great attention because they inhibit peptide synthesis synergistically by binding 
to the neighboring sites in the large ribosomal subunit.[7,8] Nucleotide sequencing 
of the largest plasmid pSLA2-L (210,614 bp) together with extensive mutational 
analysis revealed that the biosynthetic gene clusters for lankacidin (lkc) and 
lankamycin (lkm) were located on pSLA2-L.[9] This plasmid contains two 
additional biosynthetic clusters for a cryptic type-II polyketide (roc) and a 
carotenoid (crt). Furthermore, pSLA2-L carries many regulatory genes, including 
a biosynthetic gene srrX for the signaling molecules termed SRBs (S. rochei 
butenolides) and three tetR-type receptor genes (srrA, srrB, and srrC). The 
signaling molecules and their receptors play a pivotal role in the production of 
secondary metabolites in many Streptomyces species.[10] Gene inactivation 
analysis of srrX and three repressor genes, srrA, srrB, and srrC revealed that 
srrX and srrA constitute the signaling molecules/receptor system for lankacidin 
and lankamycin production in S. rochei.[11] Remarkably, disruption of srrB 
increased the production of 1 and 2 (2- and 8-fold improvement, respectively), 
suggesting that srrB has a negative function on antibiotic production. SrrB 
belongs to the signaling-molecule receptor family with high pI value (~10), which 
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act as negative regulators for antibiotic production. They are exemplified by TylQ 
for tylosin,[12] BarB for virginiamycin,[13] AlpW for kinamycins,[14] and ScbR2 for 
an unidentified polyketide with antimicrobial activity.[15] Disruption of some 
biosynthetic pathways in the producer organism can occasionally increase other 
secondary metabolite production.[16,17] Recently we reported that mutant of lkcA, 
a non-ribosomal peptide synthase (NRPS)/polyketide synthase (PKS) hybrid 
gene for lankacidin biosynthesis, produced a large amount of three polyketides, 
pentamycin, citreodiol, and epi-citreodiol (250-fold for pentamycin and 5-fold for 
citreodiols compared with the parent), although the mechanism of the complex 
metabolic changes remains unclear.[18] Hence, we expect that multiple mutations 
on both lankacidin and lankamycin biosynthetic genes together with a regulatory 
gene will activate silent secondary biosynthetic gene clusters in S. rochei.  
Here we report the isolation of an azoxyalkene compound KA57-A from a 
disruptant strain of three genes, srrB, lkcF-KR1 (a ketoreductase domain of lkcF 
for lankacidin biosynthesis), and lkmE (a type-II thioesterase gene lkmE for 
lankamycin biosynthesis). Biosynthesis of KA57-A was also studied by feeding 
of labeled acetates, amino acids, and 1-hexylamine, which is described in this 
paper. 
 
 
Results 
Isolation and structural elucidation of azoxyalkene KA57-A from the 
srrB·lkmE·lkcF-KR1 triple mutant KA57. 
   To activate silent secondary metabolite biosynthetic clusters in S. rochei, we 
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performed multiple mutations on both lankacidin and lankamycin gene clusters 
together with the transcriptional repressor srrB. Mutation targets on the lkc and 
lkm clusters were the lankacidin PKS gene lkcF-KR1 and the type-II thioesterase 
gene lkmE, whose inactivation resulted in abolishment of lankacidins and 70% 
decrease of lankamycin production, respectively.[19,20] To construct a triple 
mutant KA57 (∆srrB·∆lkmE·lkcF-KR1Y343F), plasmid pKAR1020[19] carrying 
lkcF-KR1Y343F mutation was transformed into protoplasts of the srrB-lkmE double 
mutant NS01.[20] The third mutation in strain KA57 was confirmed by Southern 
hybridization analysis. A 2.9-kb PvuI fragment in strain NS01 was changed to the 
1.2- and 1.7-kb PvuI-PstI fragments in strain KA57 (Figure S1; Supplemental 
data). Metabolites of strain KA57 were analyzed by TLC and HPLC (Figure 1). 
Strain KA57 was defective in lankacidin production due to the inactivation of 
lkcF-KR1 domain. Regarding to lankamycin production, strain KA57 produced a 
similar level of lankamycin and its derivatives compared with strain NS01. 
Remarkably, strain KA57 accumulated a UV-active compound (3), which was not 
detected in any other single or double mutants as well as the parent strain 51252 
(Figures 1A and 1B). This compound, named KA57-A, was successively purified 
by Sephadex LH20 with MeOH, and silica gel chromatographies with two 
different solvent systems of CHCl3-MeOH (50:1, v/v) and toluene-EtOAc (2:1, 
v/v). KA57-A was detected at 10.5 min on HPLC with a maximum UV 
absorbance at 238 nm, which differed from that of lankacidin C (λmax=227 nm) 
(Figure 1C). The molecular formula of KA57-A was determined by high 
resolution ESI-MS to be C10H20N2O3. Its 1H and 13C NMR assignments were 
summarized in Table 1. The 13C NMR spectrum revealed the presence of 10 
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carbons, which were classified into two methyl, four methylene, and four methine 
carbons by DEPT spectrum. In its 1H NMR, a triplet methyl proton (δH=0.92 ppm), 
a doublet methyl proton (δH=1.27 ppm), three deshielded protons (δH=3.55-3.56, 
3.73, 4.28 ppm), and two olefinic protons (δH=5.74 and 6.73 ppm) were 
observed. The coupling constant between two olefinic protons was 9.2 Hz, 
indicating the presence of a cis C=C double bond. All the spectral data agreed 
well with the reported data of 
(Z)-2-(3,4-dihydroxybutan-2-yl)-1-((Z)-hex-1-en-1-yl)diazene 1-oxide (3; Scheme 
1).[21] This compound contains unique azoxy (N=N+–O-) chromophore, and 
exhibited a weak antibiotic activity against Rhodotorula sp. Although the C-3 
configuration has been reported to be R from its CD spectra,[21] the 
stereochemistry at C-2 remained to be elucidated. Therefore, the C-2 
configuration in 3 was determined from the ∆δ (= δS-δR) value of its (R) and 
(S)-α-methoxy-α-trifluoromethyl-α-phenylacetate (MTPA) derivatives according 
to modified Mosher method.[22] The H-1 methylene protons exhibited negative 
values (-10 and -20 Hz), while the characteristic H-3, H-1’, and H-2’ proton 
signals showed positive values (+5, +25, and +15 Hz, respectively). The C-2 
configuration in 3 was thus deduced to be R. This is the first discovery of 3 from 
Streptomyces species. 
Biosynthetic origin of KA57-A  
   Naturally occurring azoxyalkene compounds constitute a fascinating group of 
secondary metabolites with a vast array of structural diversity; for example, 
elaiomycin,[23] LL-BH872α,[24] valanimycin,[25] jietacin,[26] maniwamycins,[27] and 
elaiomycins D and E (Scheme S2).[28] The well-studied azoxy-bearing natural 
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products are elaiomycin and valanimycin. According to isotope labeling studies, 
the elaiomycin skeleton is assembled from n-octylamine, L-serine, and C-2 of 
acetate.[29,30] The azoxy antibiotic valanimycin is synthesized from L-serine and 
L-valine, and its biosynthetic genes were extensively analyzed.[31] To investigate 
the biosynthetic origin of KA57-A, we carried out feeding experiments with 
isotope-labeled precursors including sodium [1-13C]acetate, sodium 
[2-13C]acetate, DL-[2,3,3-2H3]serine, [1,1-2H2]1-hexylamine, L-[15N]serine, and 
[15N]1-hexylamine.  
   The hexenyl moiety (C1’-C6’) in 3 seemed to be derived from malonyl CoA by 
a fatty acid biosynthetic pathway. Thus, [1-13C] and [2-13C]acetate were fed to 
the culture of strain KA57, and the resultant KA57-A was purified as mentioned 
above. As anticipated, the C-1 label of acetate was incorporated into the C-1’, -3’, 
and -5’ positions of KA57-A, while the C-2 label of acetate was into C-2’, -4’, and 
-6’ positions (Table 1). Remarkably, a high degree of 13C enrichment at C-1 of 3 
(δC=63.6 ppm) was observed in the feeding with sodium [2-13C]acetate.  
   A possible biosynthetic origin of the 2-aminopropanol moiety (C2-C4) was 
alanine based on its chemical structure, however, no incorporation of 
[3-13C]alanine into C-4 was observed (data not shown). We then considered 
serine as a second candidate for the origin of C2-C4. After feeding of 
DL-[2,3,3-2H3]serine to the culture, the resultant KA57-A was analyzed by 2H 
NMR (Figure 2A-ii). A distinct deuterium signal was detected at δD=1.27 ppm, 
corresponding to the C-4 methyl of KA57-A. This labeling pattern indicated that 
serine is a biosynthetic precursor for 3, and its H-2 proton (open circle in Figure 
2B) was eliminated during dehydration process in KA57-A biosynthesis.  
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   Feeding of [1,1-2H2]1-hexylamine gave a notable insight into the tailoring 
biosynthetic step of KA57-A. The resultant KA57-A was purified in a similar way, 
however, an inseparable compound appeared at the same Rf value on TLC 
(KA57-A showed a light green spot, while this contaminant did a pink spot when 
baked with anisaldehyde-H2SO4). Our further effort to separate them was 
unsuccessful even by flash chromatography on silica gel with various 
combinations of organic solvents. Because of the limited amounts available, 
further analysis was carried out as a mixture. The 2H NMR spectrum showed two 
deuterium signals at δD=6.78 and 4.14 ppm (Figure 2A-iii). The former signal 
corresponded well to H-1’ of 3 (δH=6.74 ppm), suggesting the presence of 
[1’-2H]-3 in this mixture. Its presence was further supported by detection of a 
molecular ion peak at [M+Na]+=240.1424 (calcd. for C10H192HN2O3Na, 
[M+Na]+=240.1429) in its ESI-MS spectrum (Figure 2C-i). To our surprise, an 
additional molecular ion peak ([M+Na]+=243.1645) was also observed at four 
mass units larger than that of unlabeled 3 ([M+Na]+=239.1368) (Figure 2C-i). 
Thus, electrospray ionization tandem mass spectrometry with collision-induced 
dissociations (ESI-CID-MS/MS) was applied for monitoring the isotope 
incorporation into 3 and/or its derivative. ESI-CID-MS/MS spectra for three 
parent ions at m/z 239, 240, and 243 were shown in Figure 2D. When the 
molecular ion at m/z 239 for unlabeled 3 was selected as a parent ion, a 
characteristic fragment ion [C8H14N2Na]+ was observed at m/z 161 due to the 
loss of both an ethyleneglycol cation (61 amu) and a hydroxyl anion (17 amu)  
from unlabeled 3 (hashed arrow in Figure 2D-i). An additional fragment ion 
[C4H9NO2Na]+ was also observed at m/z 126, which could be caused by 
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cleavage of the N=N bond in the azoxyalkene moiety (solid arrow in Figure 2D-i). 
ESI-CID-MS/MS analysis of [1-2H]-3 (m/z 240) showed two major fragment ions 
at m/z 162 together with m/z 126 (Figure 2D-ii). The former fragment ion 
corresponded to [C8H132HN2Na]+, which further supported the specific 
incorporation of one deuterium atom into 3. ESI-CID-MS/MS spectrum for m/z 
243 showed a distinct fragment peak at m/z 165 (Figure 2D-iii). Based on high 
resolution ESI-MS analysis, the parent (m/z 243) and its fragment (m/z 165) ions 
were established to be [C10H202H2N2O3Na]+ and [C8H142H2N2Na]+, respectively. 
Hence, this contaminant obtained by feeding of [1,1-2H2]1-hexylamine was 
presumably assigned to be [1’,1’-2H2]-1,2-dihydro-KA57-A ([1’,1’-2H2]-4). A 
deuterium signal at δD=4.14 ppm in Figure 2A-iii showed a similar chemical shift 
with the saturated methylene proton at CH2-N(-O-)=N in valanimycin (δH=4.14 
ppm),[25] supporting the presence of [1’,1’-2H2]-4 in this mixture. Compound 4 
was not detected in the fermentation broth obtained by feeding of unlabeled 
1-hexylamine (Figure 2C-ii), indicating that accumulation of [1’,1’-2H2]-4 was 
caused by a deuterium-isotope effect on the C1’-C2’ dehydrogenation step. The 
lack of a fragmentation ion at m/z 126 in ESI-CID-MS/MS spectrum for m/z 243 
(Figure 2D-iii) suggests that the clravage of the N=N bond does not occur 
without a conjugated C-1’/C-2’ double bond.  
   To investigate the origin of nitrogen atoms of KA57-A, 15N-labeled L-serine 
and 1-hexylamine were independently fed to the culture of strain KA57. 
Compound 3 obtained by feeding of L-[15N]serine showed a 15N-1H long range 
HMBC correlation from H-4 to α-nitrogen atom Nα (δN=357 ppm), while 3 
obtained by feeding of [15N]1-hexylamine showed a 15N-1H long range HMBC 
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correlation from H-2’ to β-nitrogen atom Nβ (δN=336 ppm). All the feeding 
experiments mentioned above clearly indicated that KA57-A is assembled from 
1-hexylamine (for C1’-C6’ and Nβ), serine (for C2-C4 and Nα), and C-2 of 
acetate (for C1) (Figure 2B).  
 
Discussion 
   In this study, we analyzed the structure and biosynthetic origin of the 
UV-active compound KA57-A (3) produced by the triple mutant KA57 
(∆srrB·lkcF-KR1Y343F·∆lkmE) of S. rochei. Compound 3 contains a dipolar azoxy 
(N=N+-O-) moiety that is a rare functional group among natural products 
(Scheme S2).[32] This compound was originally isolated from an aerobic 
actinomycete, Actinomadura sp. A7.[21] 
   Manipulation of regulatory pathways, by overexpression of pathway-specific 
activator genes or by inactivation of transcriptional repressor genes, is the most 
intuitive approach to activate silent biosynthetic gene clusters.[4,5] Especially, the 
latter approach provides an opportunity to activate silent biosynthetic gene 
clusters in wild-type microorganisms. A novel antibacterial activity of an 
uncharacterized product was detected in S. coelicolor after deleting the 
pseudorepressor gene scbR2, which is located within the cpk gene cluster.[15] In 
Streptomyces ambofaciens, inactivation of the tetR-type transcriptional 
repressor gene alpW led to a detectable production of kinamycins.[14] In 
Kitasatospora setae, deletion of the repressor gene ksbC resulted in lowered 
production of bafilomycin and enhanced production of a novel β-carboline 
alkaloid named kitasetaline.[33] In the case of S. rochei, mutation of srrB resulted 
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in overproduction of lankacidin and lankamycin, however, no other secondary 
metabolites were detected in this single mutant.[11] Our preliminary experiment 
indicated that srrB is involved in the signaling pathway for lankacidin and 
lankamycin production, and serves as a late stage regulator for controlling their 
titers in S. rochei (unpublished results).  
   Blockage of the competing biosynthetic pathways is also a versatile 
approach to obtain secondary metabolites of interest.[16] In the case of 
nanchangmycin production by Streptomyces nanchangensis, its titer was 
improved threefold by gene inactivation of the uncharacterized PKS cluster.[17] 
This mutation possibly affected precursor supply for nanchangmycin in this 
microorganism. In S. rochei, disruption of the NRPS/PKS hybrid gene lkcA, 
which is responsible for the early stage of lankacidin biosynthesis, caused a 
large production of three polyketides, pentamycin, citreodiol, and 
epi-citreodiol.[18] This case, however, seems different from that in S. 
nanchangensis, because their overproduction occurred only in the lkcA mutant, 
not in other lkc-PKS mutants. Analogously, compound 3 was detected only in 
strain KA57, not in any other S. rochei mutants harboring mutations on lkc, lkm, 
and their regulatory genes hitherto constructed. The mechanism of these 
complex metabolic changes in the triple mutant KA57 remains to be clarified. It is 
also noteworthy that triple mutations on the linear plasmid pSLA2-L caused 
production of 3, whose biosynthetic genes are possibly coded on the S. rochei 
chromosome. Thus, combined manipulation of regulatory gene(s) together with 
major biosynthesis clusters will become one of new momentum to activate 
cryptic biosynthetic gene clusters for natural product discovery. 
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    According to the feeding experiments with isotope-labeled precursors, 
KA57-A is assembled from 1-hexylamine (for C1’-C6’ and Nβ), serine (for C2-C4 
and Nα), and C-2 of acetate (for C1). The possible KA57-A biosynthetic pathway 
is summarized in Scheme 2. One of the interesting features in KA57-A 
biosynthesis is an unusual biosynthetic pathway of a 3-aminobutane-1,2-diol 
moiety (C1-C4 unit), which is mechanistically analogous to elaiomycin 
biosynthesis.[30] An activated serine residue receives a Claisen condensation 
with a malonyl CoA extender unit (Step 1) to yield a β-keto ester conjugate, 
which is then decarboxylated (Step 2). The resultant is converted to a possible 
biosynthetic intermediate harboring a 3-amino-1,2,4-triol moiety (Step 3) by two 
redox reactions including C-1 hydroxylation and C-2 reduction, whose order 
remains unclear.  
     The incorporation pattern of [2,3,3-2H3]serine (Figure 2A-ii) revealed that a 
dehydration reaction took place at C3-C4 positions in KA57-A biosynthesis (Step 
4). The draft genome data of S. rochei 7434AN4 revealed the presence of the 
valanimycin biosynthetic gene (vlm) homologs, vlmJ and vlmK, possibly 
encoding kinase and dehydratase, respectively. In valanimycin biosynthesis, a 
hydroxyl group of serine residue is phosphorylated by VlmJ, followed by a 
subsequent phosphate elimination by VlmK to give a dehydroalanine moiety.[31] 
It seems likely that vlmJ/vlmK homologous genes are responsible for C3-C4 
dehydration in KA57-A biosynthesis (Step 4) rather than direct dehydration by a 
single enzyme.  
Detection of [1’,1’-2H2]-4 in the feeding of [1,1-2H2]1-hexylamine (Figure 2C-i) 
gave us a notable insight for KA57-A biosynthesis. Compound 4 is possibly 
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synthesized from a C3,C4-dehydrated intermediate above mentioned by a 
stereospecific reduction (Step 5), however, 4 has not been detected in the 
culture of strain KA57 with the feeding of unlabeled 1-hexyamine (Figure 2C-ii). 
Our further effort to obtain 4 was unsuccessful even in the large-scale 
fermentation of strain KA57 (~20 L). Chromatographic isolation of [1’,1’-2H2]-4 
from the mixture of unlabeled and [1’-2H]-labeled 3 was also unsuccessful. 
These observations could be explained by a strong deuterium-isotope effect on 
the C-H/D bond cleavage at C-1’ in 4. The presence of a fully saturated hexyl 
side chain in [1’,1’-2H2]-4 indicated that C1’-C2’ dehydrogenation occurred at the 
final step in KA57-A biosynthesis (Step 6). By analogy to the valanimycin 
biosynthetic pathway,[31] O-(L-seryl)-hexylhydroxylamine (Scheme 2) is the first 
intermediate synthesized from 1-hexylamine and L-serine, although we have not 
yet detected it in S. rochei. Further genetic analysis is necessary to characterize 
the gross biosynthetic machinery of azoxyalkene compounds including the 
unique azoxy bond formation. 
 
Experimental Section 
Strains and culture conditions: S. rochei wild-type strain 7434AN4 and strain 
51252 that carries only pSLA2-L were described previously.[6,9] Strains KA07 
(∆srrB), KA35 (lkcF-KR1Y343F), and NS01 (∆srrB·∆lkmE) were constructed 
previously.[11,19,20] YEME liquid medium (0.3% yeast extract, 0.5% polypeptone, 
0.3% malt extract, 1% D-glucose, and 34% sucrose) was used for preparation of 
S. rochei protoplasts.[34] Protoplasts were regenerated on R1M agar medium.[35] 
YM medium (0.4% yeast extract, 1.0% malt extract, and 0.4% D-glucose, pH 7.3) 
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was used for secondary metabolite production. Escherichia coli XL1-Blue 
(Agilent Technologies, Santa Clara, CA, USA) was used for construction of 
targeting plasmids. E. coli strains were grown in Luria Bertani (LB) medium 
supplemented with ampicillin (100 µg mL-1) when necessary. Sodium 
[1-13C]acetate (99 atom% 13C), sodium [2-13C]acetate (99 atom% 13C), and 
L-[15N]serine (98 atom% 15N) were purchased from Isotec (Miamisburg, OH, 
USA). DL-[2,3,3-2H3]serine (98 atom% 2H) and DL-[3-13C]alanine (99 atom% 13C) 
were purchased from Cambridge Isotope Laboratories (Andover, MA, USA).  
Synthetic procedures of [1,1-2H2]1-hexylamine hydrochloride (98 atom% 2H) and 
[15N]1-hexylamine hydrochloride (49 atom% 15N) were described in 
Supplemental data. 
 
Construction of strain KA57: Plasmid pKAR1020[19] carrying Y343F mutation 
in lkcF-KR1 was transformed into protoplasts of S. rochei NS01. Transformants 
were grown in YM liquid medium supplemented with thiostrepton (10 µg mL-1) to 
give the plasmid-integrated (single crossover) strain. The thiostrepton-resistant 
colonies were subjected to a sequential cultivation in YM medium without 
thiostrepton to give a triple mutant KA57 (∆srrB·∆lkmE·lkcF-KR1Y343F). 
Disruption was confirmed by Southern blot analysis (Figure S1).   
   In a similar manipulation, strain KA36 (∆srrB·lkcF-KR1Y343F) was constructed 
by transformation of pKAR1020 into protoplasts of S. rochei KA07. 
 
Detection of metabolites: Each 100 mL of cell culture in a 500-ml Sakaguchi 
flask was incubated at 28°C for 3 days. The culture broth was extracted twice 
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with equal volume of EtOAc. The combined organic phase was dried (Na2SO4), 
filtered, and concentrated to dryness. The crude residue was analyzed by 
high-performance liquid chromatography (HPLC) and thin layer chromatography 
(TLC). The crude extract was dissolved in acetonitrile and applied on a 
COSMOSIL Cholester column (4.6 x 250 mm, Nacalai Tesque, Japan) with 
elution of a mixture of acetonitrile-10 mM sodium phosphate buffer (pH 8.2) (3:7, 
v/v) at a flow rate of 1.0 mL min-1. The eluent was monitored with a JASCO 
MD-2010 multiwavelength photodiode array detector at a scan range of 200-600 
nm. Lankacidin C (1) and azoxyalkene (3) were detected at 9.5 and 10.5 min, 
respectively. TLC (silica gel 60 F254, Merck) was developed with a mixture of 
CHCl3-MeOH (20:1, v/v), visualized by a 254-nm UV lamp, and then baked after 
spraying with anisaldehyde-H2SO4. 
 
Isolation of metabolites: The crude extract of strain KA57 from the three-days 
culture was firstly purified by Sephadex LH-20 (1.5 x 40 cm; GE Healthcare) with 
methanol. The fractions containing 3 (Rf = 0.5 in CHCl3-MeOH = 15:1) were 
combined, and then purified by a series of silica gel column chromatographies 
with two different solvent systems of CHCl3-MeOH (50:1, v/v) and 
toluene-EtOAc (2:1, v/v). Average yield of 3 was 3.3 mg L-1. 
Compound 3: [α]D25 = -40 (c=0.35, MeOH) [Ref. 21; [α]D25 = -30 (c=0.2, MeOH)]. 
HRMS (positive ESI): m/z calcd for C10H20N2O3Na: 239.1373 [M+Na]+; found: 
239.1364. The 1H and 13C NMR assignments are listed in Table 1. 
   The absolute configuration at C-2 was established by modified Mosher 
method.[22] The difference in chemical shift (∆δ) was obtained by subtracting the 
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δ value for its (R)-α-methoxy-α-trifluoromethyl-α-phenylacetate (MTPA) ester 
from that for the (S)-MTPA ester (δS-δR). 
 
Feeding experiments: Isotope-labeled substrates were independently fed at 12 
h period to two-liter cultures of strain KA57 (20 x 100 mL in the 500-mL 
Sakaguchi flasks). Isotope-labeled substrates used in this study were sodium 
[1-13C]acetate (1.0 g), sodium [2-13C]acetate (1.0 g), DL-[3-13C]alanine (100 mg), 
DL-[2,3,3-2H3]serine (100 mg), [1,1-2H2]1-hexylamine hydrochloride (200 mg), 
L-[15N]serine (100 mg), and [15N]1-hexylamine hydrochloride (50 mg). After 
cultivation for additional 2.5 days at 28°C, the resultant isotope-labeled KA57-A 
was isolated as above mentioned.  
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Table 1. NMR data for 3 in CDCl3.[a] 
Position δH (Mult., J [Hz])[b] δC (Mult.)[b] 
[c] 
[1-13C]acetate [2-13C]acetate 
1 3.56 (dd, 5.5 and 11.5) 
3.68 (dd, 3.5 and 11.5) 
63.6 (t) 1.0 2.5 
2 3.75 (m) 74.1 (d) 1.6 0.7 
3 4.30 (dt, 7.0 and 6.5) 57.6 (d) 1.1 0.9 
4 1.28 (d, 7.0) 13.4 (q) 1.0 1.0 
1’ 6.74 (dt, 9.0 and 1.5) 135.5 (d) 2.5 1.5 
2’ 5.74 (dt, 9.0 and 7.5) 134.8 (d) 1.1 2.4 
3’ 2.64 (m) 26.9 (t) 2.7 1.3 
4’ 1.46 (m) 31.1 (t) 1.1 3.0 
5’ 1.36 (m) 22.3 (t) 3.0 1.3 
6’ 0.92 (t, 7.0) 13.8 (q) 1.4 3.3 
[a] Spectra were recorded at 500 MHz for 1H and 125 MHz for 13C.  
[b] The residential solvent signal (δC = 77 ppm) and internal standard tetramethylsilane (δH = 0 ppm) were used as a reference. 
[c] Peak intensities were normalized to the 13C signal of C-4. 
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Figure and Scheme legends  
 
Scheme 1 
Structures of lankacidin C (1), lankamycin (2), and KA57-A (3) isolated from 
Streptomyces rochei strains 51252 (parent) and KA57 
(∆srrB·∆lkmE·lkcF-KR1Y343F). 
 
Scheme 2 
Proposed biosynthetic pathway of 3. Bold letters indicate hydrogen atoms from 
C2 and C3 of serine. Italic letters indicate hydrogen atoms from C-1 of 
1-hexylamine. 
 
Figure 1 
Analysis of metabolites produced by strain KA57. A) Silica gel TLC analysis of 
metabolites from various strains above mentioned: i) when irradiated with UV 
lamp at 254 nm, and ii) stained with anisaldehyde. TLC plate was developed 
with a mixture of CHCl3-MeOH (15:1, v/v). B) HPLC chromatograms obtained by 
a photodiode array detector. i) strain 51252 (parent); ii) strain KA07 (∆srrB); iii) 
strain KA36 (∆srrB·lkcF-KR1Y343F), iv) strain NS01 (∆srrB·∆lkmE); v) strain KA57 
(∆srrB·∆lkmE·lkcF-KR1Y343F); vi) purified KA57-A (3). The crude extract was 
applied on a COSMOSIL Cholester column (4.6 x 250 mm, Nacalai Tesque) and 
eluted with a mixture of acetonitrile-10 mM sodium phosphate buffer (pH 8.2) 
(3:7, v/v) at a flow rate of 1.0 mL min-1. C) The UV-visible spectra of compounds 
1 (i) and 3 (ii).  
 
Figure 2 
Biosynthetic origin of KA57-A. A) 2H-NMR spectrum of: i) unlabeled 3, ii) labeled 
3 obtained by feeding of DL-[2,3,3-2H3]serine, iii) a labeled mixture of 3 and 
1’,2’-dihydro-KA57-A (4) obtained by feeding of [1,1-2H2]1-hexylamine, and iv) 
1H-NMR spectrum of unlabeled 3. B) Proposed biosynthetic origin of KA57-A. C) 
ESI mass spectrum of a mixture containing KA57-A and its derivatives obtained 
by feeding of: i) [1,1-2H2]1-hexylamine, and ii) unlabeled 1-hexylamine. 
Chemical structures of [1’-2H]-3 and [1’,1’-2H2]-4 were also shown in this panel. 
D) ESI-CID-MS/MS spectrum of parent ions: i) m/z 239, ii) m/z 240, and iii) m/z 
243 obtained by feeding of [1,1-2H2]1-hexylamine.  
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